what is known about trial:nct:NCT07805954

Study of Zoldonrasib (RMC-9805) Plus Daraxonrasib (RMC-6236) Versus Gemcitabine and Nab-Paclitaxel as First-Line Treatment in Metastatic KRAS G12D-Mutated Pancreatic Adenocarcinoma NCT07805954↗ Outcome: Ongoing

Computed from the knowledge API (getStudy); every record links to its source.